The critical injury occurs when cyanide inhibits mitochondrial cytochrome c oxidase, disrupting the cellular respiration process that supports energy production. Detoxification therefore aims to act before this inhibition causes extensive physiological impairment. This mechanism explains why clinical toxicology emphasizes rapid recognition, prompt antidote selection, and supportive treatment rather than relying solely on the body’s natural clearance pathways.
Rhodanese detoxifies cyanide by transferring sulfur to it and producing thiocyanate, a form that can be eliminated in urine. However, the enzyme’s capacity depends on available sulfur donors. When sulfur is limited, this pathway cannot increase detoxification indefinitely, which provides the mechanistic rationale for using sodium thiosulfate to support conversion during clinical management.
Hydroxocobalamin acts by binding cyanide and forming cyanocobalamin, while sodium thiosulfate supplies sulfur that supports rhodanese-mediated conversion of cyanide into thiocyanate. These mechanisms address toxicity differently: one sequesters cyanide, whereas the other facilitates its biochemical transformation. Understanding that distinction helps clinicians relate antidote choice to the available detoxification pathways.
The principal limitation is the availability of sulfur donors for rhodanese. Although the enzyme can convert cyanide into thiocyanate, insufficient sulfur restricts the rate and extent of that reaction. This constraint means that natural detoxification may not adequately address substantial exposure, making externally supplied antidotal support relevant in emergency medicine and clinical toxicology.
Clinical antidote selection is guided by whether treatment should bind cyanide directly or support its enzymatic conversion. Hydroxocobalamin provides the binding approach by forming cyanocobalamin, while sodium thiosulfate supports thiocyanate production. Linking the treatment mechanism to cyanide’s inhibition of cellular respiration helps clinicians prioritize rapid intervention alongside supportive treatment and risk assessment.
Hydroxocobalamin converts cyanide into cyanocobalamin through binding, whereas sodium thiosulfate supports formation of thiocyanate for urinary excretion. These outcomes show how treatment can reduce the pool of biologically active cyanide through sequestration or elimination. In clinical toxicology, that distinction helps frame expectations for antidotal action and the need for continued supportive care.